SILVER SPRING, Md. – Naval Medical Research Command (NMRC), in partnership with Armata Pharmaceuticals, has completed a phase 2 clinical trial on a Staphylococcus aureus (Staph A) bacteriophage therapy.
The therapy, AP-SA02, used for the treatment of complicated bacteremia caused by S. aureus, including multidrug resistant (MDR) strains, is expected to continue to phase 3 of clinical trials in the second half of 2026.
NMRC and Armata combined efforts for the development of a bacteriophage therapy designed to provide protection against MDR bacterial infections. Following the successful completion of these trials, researchers anticipate it will arm warfighters with a readily available, faster acting treatment, as compared to traditional...
03.18.2026 | SILVER SPRING, MARYLAND, US |
Story by Aleece Williams
SILVER SPRING, Md. – Naval Medical Research Command (NMRC), in partnership with Armata Pharmaceuticals, has completed a phase 2 clinical trial on a Staphylococcus aureus (Staph A) bacteriophage therapy.
The therapy, AP-SA02, used for the treatment of complicated bacteremia caused by S. aureus, including multidrug resistant (MDR) strains, is expected to continue to phase 3 of clinical trials in the second half of 2026.
NMRC and Armata combined efforts for the development of a bacteriophage therapy designed to provide protection against MDR bacterial infections. Following the successful completion of these trials, researchers anticipate it will arm warfighters with a readily available, faster acting treatment, as compared to traditional...
03.18.2026 | SILVER SPRING, MARYLAND, US |
Story by Aleece Williams
SILVER SPRING, Md. – Naval Medical Research Command (NMRC), in partnership with Armata Pharmaceuticals, has completed a phase 2 clinical trial on a Staphylococcus aureus (Staph A) bacteriophage therapy.
The therapy, AP-SA02, used for the treatment of complicated bacteremia caused by S. aureus, including multidrug resistant (MDR) strains, is expected to continue to phase 3 of clinical trials in the second half of 2026.
NMRC and Armata combined efforts for the development of a bacteriophage therapy designed to provide protection against MDR bacterial infections. Following the successful completion of these trials, researchers anticipate it will arm warfighters with a readily available, faster acting treatment, as compared to traditional...
03.18.2026 | SILVER SPRING, MARYLAND, US |
Story by Aleece Williams
SILVER SPRING, Md. (March 18, 2026) The Daniel K. Inouye building at Forest Glen Annex, headquarters for Naval Medical Research Command (NMRC). NMRC, headquarters of Navy Medicine Research & Development, is engaged in a broad spectrum of activity from basic science in the laboratory to field studies in austere and remote areas of the world to investigations in operational environments. In support of Navy, Marine Corps and joint U.S. warfighter health, readiness and lethality, researchers study infectious diseases, biological warfare detection and defense, combat casualty care, environmental health concerns, aerospace and undersea medicine, operational mission support and epidemiology. (U.S. Navy photo by Aleece Williams/ Released)
